The FDA has expanded the use of Emergent BioSolutions' ACAM2000 smallpox vaccine to include individuals at high risk for mpox, following the WHO's designation of mpox as a global public health emergency. Emergent is donating 50,000 doses of ACAM2000 to several African countries to combat the outbreak, although the CDC warns of its higher risks compared to the Jynneos vaccine. In Singapore, the Health Sciences Authority has fully approved the Jynneos vaccine for adults at high risk for mpox or smallpox, amid concerns over the virus's rapid mutation. The approval comes as Singapore has confirmed 13 cases of mpox, prompting enhanced surveillance at borders. Meanwhile, the ongoing outbreak in Africa is primarily due to the more serious clade Ib variant, while Singapore's cases are linked to the less severe clade 2 variant. This regulatory shift reflects a broader global trend of moving towards full vaccine approvals as countries respond to the evolving mpox threat.